In addition, in the TgCRND8 model mice, activating the Nrf2-ARE pathway can attenuate the release of IL-6 and TNF-α from microglia, thereby reducing neuroinflammation[27], which means that Nrf2 may be a potential therapeutic target for AD. This evidence concerns the gene NFE2L2 and Alzheimer disease.